Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation

Journal of Clinical Investigation

Volumn 121, Issue 1, 2011, Pages 174-183

  Hu, Qianghua ^a   Gao, Fei ^a   Tian, Weihua ^a   Ruteshouser, E Cristy ^a   Wang, Yaqing ^a   Lazar, Alexander ^a   Stewart, John ^a   Strong, Louise C ^a   Behringer, Richard R ^a,b   Huff, Vicki ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b School of Biomedical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SOMATOMEDIN B RECEPTOR; WT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; GENETIC MANIPULATION; MESENCHYME; MOUSE; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION;

ANIMALS; APOPTOSIS; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA PRIMERS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENES, WILMS TUMOR; GENETIC ENGINEERING; HUMANS; INSULIN-LIKE GROWTH FACTOR II; KIDNEY; KIDNEY NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED NOD; MICE, MUTANT STRAINS; MICE, SCID; MOSAICISM; NEOPLASM TRANSPLANTATION; PREGNANCY; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION; WILMS TUMOR;

EID: 78650943634     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI43772     Document Type: Article

References (52)

1. Bardeesy N, et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet. 1994;7(1):91-97. (Pubitemid 24977994)
2. Huff V. Wilms tumor genetics. Am J Med Genet. 1998;79(4):260-267.
3. Koesters R, et al. Mutational activation of the betacatenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res. 1999; 59(16):3880-3882. (Pubitemid 29393544)
4. Maiti S, Alam R, Amos CI, Huff V. Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res. 2000;60(22):6288-6292.
5. Rivera MN, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 2007;315(5812):642-645.
6. Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer. 2008;47(6):461-470.
7. Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet. 1994;7(3):433-439.
8. Ogawa O, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature. 1993;362(6422):749-751.
9. Park S, et al. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. Nat Genet. 1993;5(4):363-367. (Pubitemid 23351307)
10. Kreidberg JA, et al. WT-1 is required for early kidney development. Cell. 1993;74(4):679-691.
11. Herzer U, Crocoll A, Barton D, Howells N, Englert C. The Wilms tumor suppressor gene Wt1 is required for development of the spleen. Curr Biol. 1999; 9(15):837-840.
12. Dao DD, et al. Genetic mechanisms of tumor-specific loss of 11p DNA sequences in Wilms tumor. Am J Hum Genet. 1987;41(2):202-217.
13. Schroeder WT, et al. Nonrandom loss of maternal chromosome 11 alleles in Wilms tumors. Am J Hum Genet. 1987;40(5):413-420.
14. Haruta M, et al. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities. Genes Chromosomes Cancer. 2008;47(8):712-727.
15. Gao F, et al. The Wilms tumor gene, Wt1, is required for Sox9 expression and maintenance of tubular architecture in the developing testis. Proc Natl Acad Sci U S A. 2006;103(32):11987-11992.
16. Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, Tilghman SM. Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature. 1995;375(6526):34-39.
17. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/ inactivation in the mouse. Dev Biol. 2002; 244(2):305-318.
18. Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nat Genet. 1995; 10(2):196-201.
19. Kaneda A, et al. Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci U S A. 2007;104(52):20926-20931.
20. Li CM, et al. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol. 2002;160(6):2181-2190.
21. Torres M, Gómez-Pardo E, Dressler GR, Gruss P. Pax-2 controls multiple steps of urogenital development. Development. 1995;121(12):4057-4065.
22. Xu PX, Adams J, Peters H, Brown MC, Heaney S, Maas R. Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia. Nat Genet. 1999;23(1):113-117. (Pubitemid 29418800)
23. Xu PX, Zheng W, Huang L, Maire P, Laclef C, Silvius D. Six1 is required for the early organogenesis of mammalian kidney. Development. 2003; 130(14):3085-3094.
24. Davies JA, et al. Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. Hum Mol Genet. 2004;13(2):235-246.
25. Yuen JS, Macaulay VM. Targeting the type 1 insulinlike growth factor receptor as a treatment for cancer. Expert Opin Ther Targets. 2008;12(5):589-603.
26. Schnabel CA, Godin RE, Cleary ML. Pbx1 regulates nephrogenesis and Ureteric branching in the developing kidney. Dev Biol. 2003;254(2):262-276.
27. Self M, et al. Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney. EMBO J. 2006;25(21):5214-5228.
28. Kobayashi A, et al. Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. Cell Stem Cell. 2008;3(2):169-181.
29. Lee SB, et al. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell. 1999;98(5):663-673.
30. Hatini V, Huh SO, Herzlinger D, Soares VC, Lai E. Essential role of stromal mesenchyme in kidney morphogenesis revealed by targeted disruption of Winged Helix transcription factor BF-2. Genes Dev. 1996;10(12):1467-1478. (Pubitemid 26260704)
31. Levinson RS, Batourina E, Choi C, Vorontchikhina M, Kitajewski J, Mendelsohn CL. Foxd1-dependent signals control cellularity in the renal capsule, a structure required for normal renal development. Development. 2005;132(3):529-539.
32. Brunskill EW, et al. Atlas of gene expression in the developing kidney at microanatomic resolution. Dev Cell. 2008;15(5):781-791.
33. Kobayashi A, Kwan KM, Carroll TJ, McMahon AP, Mendelsohn CL, Behringer RR. Distinct and sequential tissue-specific activities of the LIM-class homeobox gene Lim1 for tubular morphogenesis during kidney development. Development. 2005; 132(12):2809-2823.
34. Dressler GR, Deutsch U, Chowdhury K, Nornes HO, Gruss P. Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system. Development. 1990;109(4):787-795. (Pubitemid 20267191)
35. Takasato M, et al. Identification of kidney mesenchymal genes by a combination of microarray analysis and Sall1-GFP knockin mice. Mech Dev. 2004; 121(6):547-557.
36. Dudley AT, Lyons KM, Robertson EJ. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev. 1995;9(22):2795-807.
37. Cho EA, Patterson LT, Brookhiser WT, Mah S, Kintner C, Dressler GR. Differential expression and function of cadherin-6 during renal epithelium development. Development. 1998;125(5):803-812.
38. Shimazui T, et al. Alterations in expression of cadherin-6 and E-cadherin during kidney development and in renal cell carcinoma. Eur Urol. 2000; 38(3):331-338.
39. Kooijman R. Regulation of apoptosis by insulinlike growth factor (IGF)-I. Cytokine Growth Factor Rev. 2006;17(4):305-323.
40. Chao W, D'Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 2008;19(2):111-120.
41. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-928.
42. Fisher CE, Michael L, Barnett MW, Davies JA. Erk MAP kinase regulates branching morphogenesis in the developing mouse kidney. Development. 2001; 128(21):4329-4338. (Pubitemid 33077042)
43. Sparago A, Cerrato F, Vernucci M, Ferrero GB, Silengo MC, Riccio A. Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. Nat Genet. 2004; 36(9):958-960.
44. Prawitt D, et al. Microdeletion and IGF2 loss of imprinting in a cascade causing Beckwith-Wiedemann syndrome with Wilms' tumor. Nat Genet. 2005;37(8):785-786.
45. Stark K, Vainio S, Vassileva G, McMahon AP. Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature. 1994;372(6507):679-683.
46. Sim EU, et al. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1. Oncogene. 2002; 21(19):2948-2960.
47. Knudson AG Jr, Strong LC. Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst. 1972;48(2):313-324.
48. Lavik KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402-408.
49. Hu Q, Lu JF, Luo R, Sen S, Maity S. Inhibition of CBF/NF-Y mediated transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at G2/M phase of the cell cycle. Nucleic Acids Res. 2006;34(21):6272-6285.
50. Basson MA, et al. Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Dev Cell. 2005;8(2):229-239.
51. Tibes R, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006; 5(10):2512-2521.
52. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95(25):14863-14868.